Triple
T11074222
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | HER2 receptor |
E261824
|
entity |
| Predicate | hasAlternativeName |
P39
|
FINISHED |
| Object | HER-2/neu |
E261825
|
NE FINISHED |
How this triple was built (2 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: HER-2/neu | Statement: [HER2 receptor, hasAlternativeName, HER-2/neu]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: HER-2/neu Context triple: [HER2 receptor, hasAlternativeName, HER-2/neu]
-
A.
HER2 receptor
The HER2 receptor is a cell surface protein and member of the epidermal growth factor receptor family that, when overexpressed, drives the growth of certain aggressive breast and other cancers.
-
B.
ERBB2
chosen
ERBB2, also known as HER2, is a receptor tyrosine kinase frequently overexpressed in certain breast and other cancers and serves as a key therapeutic target.
-
C.
CA-30
CA-30 is a United States congressional district in California that encompasses parts of Los Angeles and surrounding communities and is represented in the U.S. House of Representatives.
-
D.
pertuzumab
Pertuzumab is a monoclonal antibody used in targeted therapy for HER2-positive breast cancer, often administered alongside trastuzumab and chemotherapy.
-
E.
Herceptin
Herceptin is a targeted monoclonal antibody drug used primarily to treat HER2-positive breast cancer by blocking the HER2 receptor on cancer cells.
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
Provenance (3 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69d6aa9983c08190b0ef61603b69feac |
completed | April 8, 2026, 7:20 p.m. |
| NER | Named-entity recognition | batch_69d7994e32fc8190a6591d9e82b68f75 |
completed | April 9, 2026, 12:19 p.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69e3c8cc77988190aad54f56dbd0f8cf |
completed | April 18, 2026, 6:09 p.m. |
Created at: April 8, 2026, 9:26 p.m.